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Background: Cytomegalovirus infection is associated with significant morbidity and mortality in immunocompromised
patients, but its impact on immunocompetent patients is still poorly understood. Furthermore, there is increasing
evidence implying that chronic infection may contribute to a heightened cardiovascular risk.
Case presentation: We describe the case of incidental diagnosis of Cytomegalovirus proctitis in an immune-competent
white British elderly gentleman, admitted following a stroke and investigated for rectal cancer following the development
of bloody diarrhoea and persistent systemic inflammatory response.
Conclusion: This raised some several interesting points; firstly that we must revise our approach to investigating the
immunocompetent elderly patient, secondly, could chronic Cytomegalovirus infection have contributed to the
presentation of stroke in this patient and lastly what are the existing evidence for treatment in this population? We use
this opportunity to try and address some of these questions and feel that this would be of benefit to the wider audience.
We discuss the risk factors for disease in immune-competent patients and also a brief overview of the benefits of
treatment in this population.
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Cytomegalovirus (CMV) infection is a recognised cause of
significant morbidity and mortality in immunocomprom-
ised patients due to the inability to curb viral replication.
The clinical manifestations and duration of symptoms that
are seen appear to vary between susceptible groups [1].
Conversely, its impact on immunocompetent patients is
still poorly understood. In recent years, the definitions of
immunocompetent have been questioned; in this case, we
use the term immunocompetent to describe those who
are not undergoing chemotherapy or infected with human
immunodeficiency virus (HIV). However, we describe an
elderly gentleman with multiple co-morbidities whom falls
under the spectrum of a broader group of patients who do
not have an intact cell-mediated immunity and are suscep-
tible to opportunistic infections [2]. This is becoming an
increasing challenge for clinicians who are being faced* Correspondence: sathyavani81@gmail.com
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unless otherwise stated.with such scenarios: a lack of understanding of the path-
ology of CMV infection and age-related immune changes
may lead to a delay in diagnosis and a potential need for
treatment. This case highlights the need to be vigilant, es-
pecially in those who present with symptoms that are ‘out-
side the box’.
Case presentation
We present the case of a 79-year-old white British man on
the Acute Stroke unit undergoing Stroke care following a
recent left MCA territory Infarct. Past medical history in-
cluded hypertension, uncontrolled type 2 diabetes and
chronic kidney disease stage 3.
During the first few weeks of his admission, his stay was
complicated by both an acute NSTEMI with a concomi-
tant troponin-I rise of 4.9 ng/ml (reference levels: 0.0 –
0.04 ng/ml) and systemic inflammatory response. He was
initially pyrexial and blood tests revealed a total white cell
count (WCC) of 16.5 × 109/L (rising from 12×109/L on
admission, neutrophils count 13.0×109/L) and a C-reactive
protein (CRP) of 107 mg/L (from 56 mg/L on admission).ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cluded dual anti-platelet therapy.
It was felt that the respiratory system could clinically rep-
resent the most likely source of infection although a chest
radiogram did not show any consolidation. In view of
raised inflammatory markers and ongoing pyrexia, the pa-
tient was treated empirically with piperacillin-tazobactam.
A full septic screen, including, one set of blood cultures,
sputum and urine sample were sent for microbiology cul-
ture, which essentially had no significant growth.
His clinical state continued to fluctuate necessitating a
change in antibiotic regime to intravenous meropenem,
which after 5 days led to an improvement in the patient’s
clinical state with associated resolving inflammatory
markers.
A non-enhanced computed tomography (CT) chest,
abdomen and pelvis was performed. Concentric wall
thickening of the rectum and fat stranding of the peri-
rectal fascia were the main abnormalities noted with a
differential diagnosis of bowel inflammatory process or
underlying malignancy (Figure 1).
However, he developed diarrhoea (type 7 on the Bristol
chart), and intermittent per-rectal bleeding with an asso-
ciated drop in haemoglobin (Hb) from 12.9 g/dl to
9.3 g/dl. The dual antiplatelet therapy was stopped and
multiple stool cultures were sent. Glutamate dehydro-
genase (GDH) and Clostridium difficile toxins and cul-
tures for enteric community pathogens were all negative.
The bleeding was associated with a recurrence of fevers
(daily temperatures greater than 38°C) but normal in-
flammatory markers. Due to the swinging fevers and PR
bleeding, attempts were made to directly visualize and
biopsy the area of rectal thickening, but it took severalFigure 1 Computed tomography (CT) image of the lower abdomen. R
stranding of the perirectal fascia.days before this was achievable, by which point his fe-
vers and bleeding had once again normalised.
Ultimately, flexible sigmoidoscopy revealed what ap-
peared to resemble an ulcerating rectal cancer with a large
blind ending malignant cavity. Biopsies were taken and the
histological evaluation showed acutely inflamed granula-
tion tissue and ulcer slough, associated with scattered en-
larged cells (with eosinophilic nuclear inclusions, Figure 2).
Immunostaining was positive for CMV (Figure 3). The
histological examination did not confirm any evidence of
malignancy. As such, advice and specific tests were sought
from the infectious diseases team. CMV viral load was 300
copies/ml; CMV PCR on the fixed tissue sample detected
the presence of specific CMV DNA and serological sam-
ples showed the presence of CMV IgG and absence of IgM
(past infection). An HIV test was negative. The case was
discussed in a multidisciplinary meeting where the consen-
sus was that this was CMV proctitis resulting in rectal
ulceration.
Discussion
Cytomegalovirus (CMV) is a double stranded DNA virus,
member of the herpesviridae family [3]. It is a highly suc-
cessful human pathogen, which may be, transmitted both
vertically and horizontally without an obvious clinical
affect on the host. Worldwide, it is estimated that the
sero-prevalence of CMV infection is between 40-100% [4],
with the largest numbers affecting those from Asia and
Africa and high-risk populations. After the initial infec-
tion, CMV may persist in a state of latency; effective con-
trol of the virus is dependent on an intact CD4+ and CD8
+ cell mediated immunity [5]. However, there may still be
intermittent asymptomatic viral shedding in both theed arrow shows concentric wall thickening of the rectum and fat
Figure 2 Haemtoxylin and eosin (H&E) stained slide × 400 showing inflamed granulation tissue containing an enlarged cell with
cytomegalovirus inclusion.
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compromised individuals [6].
CMV may manifest itself at the time of the initial in-
fection (primary infection) or at a later stage (second-
ary), which may be due to reactivation of the latent
infection or re-infection via a new exogenous strain [3].
In immunocompromised patients, the inability to con-
trol viral replication forms the cornerstone of the devas-
tating disease manifestations that are seen. In contrast,Figure 3 Immunostaining x 400 for cytomegalovirus shows strong pothe course run by those with a competent immune sys-
tem can be more varied. Whilst the majority of those
affected may be asymptomatic or present with a general-
ized mononucleosis-like syndrome, other clinical manifes-
tations are not as infrequent as previously thought [2].
The gastrointestinal tract is the most common site
affected by CMV in immune-competent patients with a
predilection for the colon and rectum [2]. However, the
term immunocompetent could be considered a misnomersitivity.
Subbarao et al. BMC Research Notes 2014, 7:799 Page 4 of 5
http://www.biomedcentral.com/1756-0500/7/799in certain situations. Previous studies have shown that
CMV colitis spontaneously resolves in patients <55 years
[7]. Conversely, specific groups such as diabetics,
age ≥55 years, chronic renal failure, pregnancy and
untreated non-haematological malignancy appear to
adversely influence survival [7]. It is known that all
these conditions do have a modulatory affect on the
immune system; for example, both aging and diabetes
are associated with a decline in cell-mediated immunity
and a dysregulation in the cytokine responses, which is
reflected by the increase in the numbers of overall infec-
tions [8]. In fact, age-associated dysregulation in the im-
munity (Immune-senescence) is becoming increasingly
well characterised. Aging is associated with reduced pool
of naïve T cells and CMV infection further compounds
this, through expansion of CMV specific CD8+ and CD4+
memory T cells [9]. Moreover, observational data shows
that CMV sero-positivity increases the risk of cardiovascu-
lar death in individuals over the age of 65 years [10]. Thus,
whilst these groups of patients are not immunocomprom-
ised in the traditional sense, they certainly do not have a
preserved immunity and should be investigated as such.
As a testimony to this, our patient was indeed afflicted by
a number of co-morbidities that would be altering his im-
mune responses: advanced age, uncontrolled type 2 dia-
betes and renal impairment. If this gentleman was infected
by the human immune-deficiency virus (HIV) and had
presented with per-rectal bleeding, he would have had a
CMV PCR performed immediately as part of routine in-
vestigations, especially in view of the abnormalities seen
on the CT scan.
In this case, the diagnosis of CMV infection was an in-
cidental finding, based on the presence of intranuclear
inclusion bodies at the histological examination. These
inclusions are known as owl’s eye bodies, which stain
dark pink on haematoxylin and eosin stain [11]. We also
demonstrated the molecular amplification of the viral
DNA within the tissue and a low level viraemia was seen
several weeks after the onset of symptoms. We can
speculate that in this case, CMV proctitis was due to a
re-activation of a latent infection evidenced by the pres-
ence of IgG antibodies and absence of IgM. Whether the
initial presentation arose as a consequence of systemic
sepsis or whether there was a high CMV viraemia at the
start of admission driving the sepsis like syndrome re-
mains to be elucidated. The cytokine effects of sepsis
driving CMV viraemia have previously been described; it
is appears that the presence of pro-inflammatory cyto-
kines, tumour necrosis factor-alpha (TNF-alpha) and
interleukin (IL)-1 beta in the early stages of sepsis reacti-
vate CMV from latency [12]. Furthermore, the later
stages of sepsis are characterized by immunosuppressant
interleukins such as IL-10 and IL-4 [13]. These are be-
lieved to be involved in CMV proliferation followingreactivation. However, several courses of broad-spectrum
antibiotics failed to completely control the systemic in-
flammatory response in this patient, suggesting that this
might have been driven by a large CMV viraemia. A recent
systematic review identifying the contribution of CMV to
outcomes in the critical care unit showed that CMV infec-
tion occurred in 0-36% of critically ill patients and the risk
of CMV infection was five-fold higher in those patients
presenting with sepsis [14]. A further question arising
from this case is whether CMV itself was an independent
driver of the stroke and myocardial infarction, rather than
just a bystander. Several studies previously, have shown
that uncontrolled viraemia in HIV-infected patients have a
higher cardiovascular risk compared to patients with un-
detectable viral loads on anti-retroviral therapy [15]. Simi-
larly, in vitro studies have demonstrated that CMV
directly invades endothelial cells and has potent procoagu-
lant properties [16]. There is no current causal link be-
tween CMV seroprevalence and atheroma formation.
However, epidemiological evidence shows accelerated ath-
erosclerosis in the presence of CMV in patients following
cardiac transplantation [17].
By the time the diagnosis of CMV proctitis was reached,
patient’s symptoms had subsided, therefore obviating the
need for treatment. However, there are no randomized
controlled trials examining the role for antivirals in this
population, with limited evidence available. Whilst the in-
cidence of CMV-related disease in the immunocompetent
population may be increasing, many recover without
intervention. It would therefore be impractical to conduct
a large randomized trial establishing clinical efficacy and
toxicity. We therefore advocate the use of antivirals in
such patients on a named basis, balancing the risks and
benefits of treatment.
Conclusion
This case highlights an unusual clinical presentation of
CMV proctitis in a patient whom rectal cancer was ini-
tially top of the differential diagnosis. The endoscopic and
radiological findings, which were finally attributed to
CMV infection, mimicked a malignancy. Whilst exclusion
of a cancerous lesion was clearly a priority, this lead to a
delay in the diagnosis of the CMV infection. Moreover,
the persistent systemic inflammatory response was likely
to have been secondary to a chronic CMV viraemia rather
than an overt bacterial sepsis; additionally we pose the
question of whether an uncontrolled viraemia could have
contributed to the initial stroke. We therefore suggest that
a high index of suspicion is important for an early diagno-
sis and potential instigation of treatment.
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